These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 29059766

  • 1. Re: Oxalobacter formigenes Colonization Normalizes Oxalate Excretion in a Gastric Bypass Model of Hyperoxaluria.
    Assimos DG.
    J Urol; 2017 Nov; 198(5):974-975. PubMed ID: 29059766
    [No Abstract] [Full Text] [Related]

  • 2. Oxalobacter formigenes colonization normalizes oxalate excretion in a gastric bypass model of hyperoxaluria.
    Canales BK, Hatch M.
    Surg Obes Relat Dis; 2017 Jul; 13(7):1152-1157. PubMed ID: 28552742
    [Abstract] [Full Text] [Related]

  • 3. Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter.
    Hatch M, Gjymishka A, Salido EC, Allison MJ, Freel RW.
    Am J Physiol Gastrointest Liver Physiol; 2011 Mar; 300(3):G461-9. PubMed ID: 21163900
    [Abstract] [Full Text] [Related]

  • 4. Oxalobacter formigenes-Derived Bioactive Factors Stimulate Oxalate Transport by Intestinal Epithelial Cells.
    Arvans D, Jung YC, Antonopoulos D, Koval J, Granja I, Bashir M, Karrar E, Roy-Chowdhury J, Musch M, Asplin J, Chang E, Hassan H.
    J Am Soc Nephrol; 2017 Mar; 28(3):876-887. PubMed ID: 27738124
    [Abstract] [Full Text] [Related]

  • 5. Intestinal Oxalobacter formigenes colonization in calcium oxalate stone formers and its relation to urinary oxalate.
    Troxel SA, Sidhu H, Kaul P, Low RK.
    J Endourol; 2003 Apr; 17(3):173-6. PubMed ID: 12803990
    [Abstract] [Full Text] [Related]

  • 6. Sel1-like proteins and peptides are the major Oxalobacter formigenes-derived factors stimulating oxalate transport by human intestinal epithelial cells.
    Arvans D, Chang C, Alshaikh A, Tesar C, Babnigg G, Wolfgeher D, Kron S, Antonopoulos D, Bashir M, Cham C, Musch M, Chang E, Joachimiak A, Hassan H.
    Am J Physiol Cell Physiol; 2023 Jul 01; 325(1):C344-C361. PubMed ID: 37125773
    [Abstract] [Full Text] [Related]

  • 7. Oxalobacter formigenes and its potential role in human health.
    Duncan SH, Richardson AJ, Kaul P, Holmes RP, Allison MJ, Stewart CS.
    Appl Environ Microbiol; 2002 Aug 01; 68(8):3841-7. PubMed ID: 12147479
    [Abstract] [Full Text] [Related]

  • 8. Oxalobacter formigenes treatment confers protective effects in a rat model of primary hyperoxaluria by preventing renal calcium oxalate deposition.
    Verhulst A, Dehmel B, Lindner E, Akerman ME, D'Haese PC.
    Urolithiasis; 2022 Apr 01; 50(2):119-130. PubMed ID: 35122487
    [Abstract] [Full Text] [Related]

  • 9. Enteric hyperoxaluria: role of microbiota and antibiotics.
    Liu M, Nazzal L.
    Curr Opin Nephrol Hypertens; 2019 Jul 01; 28(4):352-359. PubMed ID: 31145706
    [Abstract] [Full Text] [Related]

  • 10. ePHex: a phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria.
    Ariceta G, Collard L, Abroug S, Moochhala SH, Gould E, Boussetta A, Ben Hmida M, De S, Hunley TE, Jarraya F, Fraga G, Banos A, Lindner E, Dehmel B, Schalk G.
    Pediatr Nephrol; 2023 Feb 01; 38(2):403-415. PubMed ID: 35552824
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria.
    Hoppe B, Niaudet P, Salomon R, Harambat J, Hulton SA, Van't Hoff W, Moochhala SH, Deschênes G, Lindner E, Sjögren A, Cochat P.
    Pediatr Nephrol; 2017 May 01; 32(5):781-790. PubMed ID: 27924398
    [Abstract] [Full Text] [Related]

  • 14. Oxalobacter formigenes: Opening the door to probiotic therapy for the treatment of hyperoxaluria.
    Jairath A, Parekh N, Otano N, Mishra S, Ganpule A, Sabnis R, Desai M.
    Scand J Urol; 2015 May 01; 49(4):334-7. PubMed ID: 25645091
    [Abstract] [Full Text] [Related]

  • 15. [Oxalobacter formigenes--characteristics and role in development of calcium oxalate urolithiasis].
    Torzewska A.
    Postepy Hig Med Dosw (Online); 2013 Nov 27; 67():1144-53. PubMed ID: 24379255
    [Abstract] [Full Text] [Related]

  • 16. Reduction of plasma oxalate levels by oral application of Oxalobacter formigenes in 2 patients with infantile oxalosis.
    Hoppe B, Dittlich K, Fehrenbach H, Plum G, Beck BB.
    Am J Kidney Dis; 2011 Sep 27; 58(3):453-5. PubMed ID: 21705122
    [Abstract] [Full Text] [Related]

  • 17. [Oxalate: a poorly soluble organic waste with consequences].
    Lu Y, Bonny O.
    Praxis (Bern 1994); 2015 Mar 25; 104(7):353-9. PubMed ID: 25804778
    [Abstract] [Full Text] [Related]

  • 18. Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: possible prevention by gut recolonization or enzyme replacement therapy.
    Sidhu H, Schmidt ME, Cornelius JG, Thamilselvan S, Khan SR, Hesse A, Peck AB.
    J Am Soc Nephrol; 1999 Nov 25; 10 Suppl 14():S334-40. PubMed ID: 10541258
    [Abstract] [Full Text] [Related]

  • 19. Hyperoxaluria, hypocitraturia, hypomagnesiuria, and lack of intestinal colonization by Oxalobacter formigenes in a cervical spinal cord injury patient with suprapubic cystostomy, short bowel, and nephrolithiasis.
    Vaidyanathan S, von Unruh GE, Watson ID, Laube N, Willets S, Soni BL.
    ScientificWorldJournal; 2006 Apr 06; 6():2403-10. PubMed ID: 17619709
    [Abstract] [Full Text] [Related]

  • 20. Re: A Randomised Phase I/II Trial to Evaluate the Efficacy and Safety of Orally Administered Oxalobacter formigenes to Treat Primary Hyperoxaluria.
    Assimos DG.
    J Urol; 2017 Jun 06; 197(6):1463. PubMed ID: 28505910
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.